HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutamide in vitro

Castration-resistant prostate cancer (CRPC) continues to be a major challenge in the treatment of prostate cancer (PCa). The expression of hepatocyte cell adhesion molecule (HepaCAM), a novel tumor suppressor, is frequently downregulated or lost in PCa. Overactivated Notch signaling is involved in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Zhongbo, Li, Luo, Sun, Wei, Wang, Xiao, Zhang, Yao, Chen, Zhixiong, Yuan, Mengjuan, Quan, Zhen, Liu, Nanjing, Hao, Yanni, Li, Ting, Wang, Jinhua, Luo, Chunli, Wu, Xiaohou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958706/
https://www.ncbi.nlm.nih.gov/pubmed/29658567
http://dx.doi.org/10.3892/ijo.2018.4370

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958706/
https://www.ncbi.nlm.nih.gov/pubmed/29658567
http://dx.doi.org/10.3892/ijo.2018.4370

Ejemplares similares